Occudo Quantitative Strategies LP Allakos Inc. Transaction History

Occudo Quantitative Strategies LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $22,541 - $58,735	10,583 New	10,583 $24,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $113,630 - $169,039	20,076 New	20,076 $169,000
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $67,137 - $158,547	-25,822 Reduced 15.65%	139,210 $436,000
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $193,537 - $373,741	38,098 Added 30.01%	165,032 $941,000
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $1.06 Million - $13.9 Million	124,396 Added 4901.34%	126,934 $1.24 Million
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $2,755 - $3,975	-36 Reduced 1.4%	2,538 $269,000
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $219,742 - $293,693	2,574 New	2,574 $220,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.